A Phase 1-2 Study of AZD5492 in People With B-Cell Cancers

Full Title

A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium)

Purpose

Researchers want to find the best dose of AZD5492, a new type of immunotherapy, to treat people with B-cell cancers that keep growing after treatment. These cancers include:

• Large B-cell lymphoma
• Follicular lymphoma
• Mantle cell lymphoma
• Chronic lymphocytic leukemia/small lymphocytic leukemia

AZD5492 is called a T cell-engaging antibody. AZD5492 helps the immune system target and eliminate cancer cells.

Who Can Join

To join this study, there are a few conditions. You must:

• Have a B-cell cancer that keeps growing after treatment and has the CD20 protein.
• Have recovered from the serious side effects of previous therapies before getting AZD5492.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Lorenzo Falchi’s office at 646-608-3705.